Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 157

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 157
---
3,250,000 Ordinary Shares represented by 325 Depositary Shares at $4,640.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 1,293 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 1,939 Depositary Shares, issuable upon the exercise of Series B Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 6,218 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the private placement at an exercise price of $0.80 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered placement agent warrants to purchase a total of 536,800 Ordinary Shares represented by 52 Depositary Shares toLadenburg Thalmann & Co. Inc., or Ladenburg, at an exercise price of $10,000.00 per warrant for one warrants and an exercise price of $5,800.00 per warrant for 51 warrants, and Series A Warrants to purchase 625,000 Ordinary Shares represented by 62 Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to a waiver.

| II-1 |

On May 26, 2023,
in a private placement with certain institutional investors, we sold (1) 166,017,700 Ordinary Shares represented by 16,601 Depositary
Shares, issuable upon the exercise of the Series C Warrants at an exercise price of $400.00 per warrant, (2) 110,675,600 Ordinary Shares
represented 11,059 Depositary Shares issuable upon the exercise of the Series D Warrants at an exercise price of $400.00 per warrant and,
(3) 4,426,800 Ordinary Shares represented by 442 Depositary Shares issuable upon the exercise of the May 2023 Placement Agent Warrants
at an exercise price of $375.00 per warrant.

On December 21, 2023, in two private placement
transactions, we issued (i) an aggregate of 8,997 Depositary Shares to certain secured noteholders of Adhera Therapeutics, Inc., and (y